Uptravi - (0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 mg; Tablet,)

Generic Name	Selexipag	**Innovator**	Actelion pharmaceuticals
Dosage	0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 mg; Tablet,	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	None
Indication	UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Uptravi - (1.8 mg/vial ; Powder, Intravenous)

Generic Name	Selexipag	**Innovator**	ACTELION
Dosage	1.8 mg/vial ; Powder, Intravenous	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	None	**Tentative Approvals**	Less Than 5
Final Approvals	None	**Generic Launches**	None
Indication	UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.